|
2026 Journal Article Advances in biomarkers for mantle cell lymphoma in the era of targeted therapiesLoh, Zoe, Yeh, Paul, Keane, Colm and Hawkes, Eliza A. (2026). Advances in biomarkers for mantle cell lymphoma in the era of targeted therapies. Haematologica, 111 (4), 1198-1214. doi: 10.3324/haematol.2025.288185 |
|
2026 Journal Article Same-Slide Spatial Multi-Omics Integration with IN-DEPTH Reveals Tumor Virus-Linked Spatial Reorganization of the Tumor MicroenvironmentYiu, Stephanie Pei Tung, Chang, Yuzhou, Yeo, Yao Yu, Qiu, Huaying, Wu, Wenrui, Michel, Hendrik A., Jin, Xiaojie, Huang, Rongting, Kure, Shoko, Parmelee, Lindsay, Luo, Shuli, Cramer, Precious, Lee, Jia Le, Wang, Yang, Zhao, Zhangxin, Yeung, Jason, El Ahmar, Nourhan, Simsek, Berkay, Mohanna, Razan, Van Orden, McKayla, Lu, Wesley S., Livak, Kenneth J., Li, Shuqiang, Gao, Ce, Burgess, Melinda, Keane, Colm, Shahryari, Jahanbanoo, Kingsley, Leandra G., Al-Humadi, Reem N. ... Jiang, Sizun (2026). Same-Slide Spatial Multi-Omics Integration with IN-DEPTH Reveals Tumor Virus-Linked Spatial Reorganization of the Tumor Microenvironment. Cancer Discovery. doi: 10.1158/2159-8290.cd-25-0775 |
|
2026 Conference Publication Differential immune suppression in PCNSL and GBM reveals checkpoint dependencies underlying CNS therapy responseTuczko, Nella Martyna, Keane, Colm, Hawula, Zachary, Burgess, Melinda, Chowdhury, Rakin, Bradbury, Lucy and Swain, Fiona (2026). Differential immune suppression in PCNSL and GBM reveals checkpoint dependencies underlying CNS therapy response. AACR Special Conference in Cancer Research: Brain Cancer, Philadelphia, PA, United States, 23-25 March 2026. Philadelphia, PA, United States: American Association for Cancer Research. doi: 10.1158/1538-7445.BRAIN26-A005 |
|
2026 Journal Article Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II ‘FLUORO’ studyMartynchyk, Arina, Chong, Geoffrey, Khor, Richard, Lee, Denise, Lee, Sze Ting, Scott, Andrew M., Grobler, Anneke C., Campbell, Belinda A., Thachil, Thanuja, Manos, Kate, Douglas, Genevieve, Romano, Alexandra, Palmer, Jodie B., Burgess, Melinda, Keane, Colm and Hawkes, Eliza A. (2026). Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II ‘FLUORO’ study. British Journal of Haematology bjh.70468. doi: 10.1111/bjh.70468 |
|
2025 Conference Publication Pembrolizumab (Pembro) plus R-CHOP is efficacious as first-line therapy for primary mediastinal B-cell lymphoma (PMBL) with high rates of ctdna negativity – interim efficacy analysis of the ALLG-Pacific (NHL35) trialLewis, Katharine, Blombery, Piers, Sungala, Nagendra Prasad, Giri, Pratyush, Marconi, Tamara, Cochrane, Tara, Francis, Roslyn, Lee, Sze-Ting, Ma, Chun Kei Kris, Vanguru, Vinay, Manos, Kate, Keane, Colm, Hunter, Sally, Burgess, Melinda, Kannan, Sushmitha, Carlson, Julia, Walia, Mannu, Butcher, Belinda and Cheah, Chan (2025). Pembrolizumab (Pembro) plus R-CHOP is efficacious as first-line therapy for primary mediastinal B-cell lymphoma (PMBL) with high rates of ctdna negativity – interim efficacy analysis of the ALLG-Pacific (NHL35) trial. 67th American Society of Hematology Annual Meeting and Exposition, Orlando, FL United States, 6–9 December 2025. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2025-1016 |
|
2025 Conference Publication Divergent immune programs in EBV⁺ PCNSL: a multiomic study of AR-PCNSL and cns-PTLDBurgess, Melinda, Hawula, Zachary, Kempe, Sarah, Murigneux, Valentine, Swain, Fiona, Chowdhury, Rakin, Tuczko, Nella, Bradbury, Lucy, Antczak, Magdalena, Mehdi, Ahmed, Hawkes, Eliza, Wight, Joel, Gould, Clare, Gandhi, Maher, Jiang, Sizun, Maguire, Alanna and Keane, Colm (2025). Divergent immune programs in EBV⁺ PCNSL: a multiomic study of AR-PCNSL and cns-PTLD. 67th ASH Annual Meeting, Orlando, FL USA, 6-9 December 2025. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2025-457 |
|
2025 Conference Publication Multiomic dissection of immune-privileged DLBCL reveals divergent immune subtypes in testicular and primary central nervous system lymphomaBurgess, Melinda, Hawula, Zachary, Tuczko, Nella, Kempe, Sarah, Murigneux, Valentine, Swain, Fiona, Chowdhury, Rakin, Bradbury, Lucy, Antczak, Magdalena, Mehdi, Ahmed, Hawkes, Eliza, Wight, Joel, Henden, Andrea, Sheehy, Joshua, Gandhi, Maher, Jiang, Sizun and Keane, Colm (2025). Multiomic dissection of immune-privileged DLBCL reveals divergent immune subtypes in testicular and primary central nervous system lymphoma. 67th ASH Annual Meeting and Exposition, Orlando, FL, United States, 6-9 December 2025. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood-2025-147 |
|
2025 Conference Publication Expression of the cancer testis antigen PRAME is associated with response to immune checkpoint inhibitor and rituximab priming in treatment-naïve diffuse large B-cell lymphomaManos, Kate, Burgess, Melinda, Chong, Geoffrey, Lee, Sze-Ting, Smith, Charmaine, Renwick, William, Kempe, Sarah, Murigneux, Valentine, Chowdhury, Rakin, Blombery, Piers, Nelson, Niles, Fancourt, Tineke, Hawking, Joanne, Lin, Wendi, Barraclough, Allison, Wight, Joel, Keane, Colm and Hawkes, Eliza (2025). Expression of the cancer testis antigen PRAME is associated with response to immune checkpoint inhibitor and rituximab priming in treatment-naïve diffuse large B-cell lymphoma. 67th ASH Annual Meeting, Orlando, FL, United States, 6-9 December 2025. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood-2025-3306 |
|
2025 Conference Publication Distinct immune checkpoint landscapes in PCNSL and SCNSL revealed by single-nucleus profilingHawula, Zachary, Tuczko, Nella, Burgess, Melinda, Bradbury, Lucy, Chowdhury, Rakin, Swain, Fiona, Hawkes, Eliza, Wight, Joel and Keane, Colm (2025). Distinct immune checkpoint landscapes in PCNSL and SCNSL revealed by single-nucleus profiling. 67th ASH Annual Meeting, New Orleans, LA, United States, 12-15 December, 2025. New York, NY, United States: Elsevier. doi: 10.1182/blood-2025-149 |
|
2025 Conference Publication Trial in progress: Treatment of CNS lymphoma with zanubrutinib and tislelizumab: A phase ib/II investigator-initiated studySalvaris, Ross, Keane, Colm, Trotman, Judith, Sutherland, Antony, Waltham, Mark, Simpson, David, Gregory, Gareth P. and Opat, Stephen (2025). Trial in progress: Treatment of CNS lymphoma with zanubrutinib and tislelizumab: A phase ib/II investigator-initiated study. 67th ASH Annual Meeting, Orlando, FL, United States, 6-9 December 2025. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood-2025-1926 |
|
2025 Journal Article Meeting trial eligibility in follicular lymphoma patients is associated with overall survival but not progression-free survivalWong, Kimberly S. Q., Martynchyk, Arina, Krisnadi, Zoe, Swain, Fiona, Zargari, Ahmad, Cassidy, Luke, Mills, Georgia, Lim, Kenneth, Gervasi, Jeremy, Smallbone, Portia, Wang, Jenny, Slifirski, Olivia, Loh, Zoe, Cheah, Chan, Keane, Colm, Gregory, Gareth, Lasica, Masa, Chong, Geoffrey, Barraclough, Allison, Cochrane, Tara, Lee, Denise and Hawkes, Eliza (2025). Meeting trial eligibility in follicular lymphoma patients is associated with overall survival but not progression-free survival. JNCI: Journal of the National Cancer Institute, 117 (11) djaf174, 2240-2248. doi: 10.1093/jnci/djaf174 |
|
2025 Conference Publication Characterizing the mechanistic role of TNF signaling via TNFR1 and TNFR2 on NK cell-mediated anti-tumor immunityAlim, Louisa Frances, Lam, Pui Yeng, Keane, Colm and Souza-Fonseca-Guimaraes, Fernando (2025). Characterizing the mechanistic role of TNF signaling via TNFR1 and TNFR2 on NK cell-mediated anti-tumor immunity. Immunology 2025™ Meeting, Honolulu, HI United States, 3-7 May 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/jimmun/vkaf283.730 |
|
2025 Journal Article T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a Phase I trialHawkes, Eliza A., Palmer, Jodie, Khor, Richard, Lee, Sze Ting, Burgess, Melinda, Law, Soi C., Gandhi, Maher K., Chong, Geoffrey, Shortt, Jake, Chowdhury, Rakin, Swain, Fiona, Churilov, Leonid, MacManus, Michael M., Smith, Charmaine, Scott, Fiona Elizabeth, Martynchyk, Arina, Barraclough, Allison, Manos, Kate, Scott, Andrew M. and Keane, Colm (2025). T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a Phase I trial. Blood Advances, 9 (20), 5263-5273. doi: 10.1182/bloodadvances.2025016505 |
|
2025 Journal Article T cell immune profile changes predict durable response to nivolumab-rituximab in treatment naïve FLKoldej, Rachel M., Barraclough, Allison, Morgan, Huw, Lee, Sze Ting, Holzwart, Nicholas, Koshy, Minu, Smith, Charmaine, Chong, Geoff, Gilbertson, Michael, Keane, Colm, Lee, Denise, Churilov, Leonid, Ritchie, David S. and Hawkes, Eliza A. (2025). T cell immune profile changes predict durable response to nivolumab-rituximab in treatment naïve FL. Blood Neoplasia, 2 (4) 100168, 1-5. doi: 10.1016/j.bneo.2025.100168 |
|
2025 Journal Article T-cell receptor repertoires show dynamic variation between diagnosis and relapse of diffuse large B-cell lymphomaWight, Joel, Witkowski, Tom, Keane, Colm and Hawkes, Eliza A. (2025). T-cell receptor repertoires show dynamic variation between diagnosis and relapse of diffuse large B-cell lymphoma. eJHaem, 6 (4) e70097, 1-5. doi: 10.1002/jha2.70097 |
|
2025 Conference Publication Novel escalation of radiotherapy dose and treated volume augments immunotherapy in B-cell lymphoma: results from a phase I trial (RaDD Study)Scott, Andrew, Palmer, Jodie, Lee, Sze ting, Khor, Richard, Burgess, Melinda, Chong, Geoff, Shortt, Jake, Chowdury, Rakin, Swain, Fiona, Churilov, Leonard, Macmanus, Michael, Smith, Charmaine, Scott, Fiona, Martynchyk, Arina, Barraclough, Allison, Manos, Kate, Keane, Colm and Hawkes, Eliza (2025). Novel escalation of radiotherapy dose and treated volume augments immunotherapy in B-cell lymphoma: results from a phase I trial (RaDD Study). 2025 SNMMI Annual Meeting, New Orleans, LA USA, 21-24 June 2025. Reston, VA United States: Society of Nuclear Medicine. |
|
2025 Conference Publication Australian patients with relapsed or refractory diffuse large B‐cell lymphoma frequently fail eligibility criteria for landmark and registration clinical trialsGoodall, E., Palmer, J., Martynchyk, A., Waters, N., Swain, F., Marconi, T., Giang, T. B., Brennan, J., Gregory, G., Cheah, C., Keane, C. and Hawkes, E. (2025). Australian patients with relapsed or refractory diffuse large B‐cell lymphoma frequently fail eligibility criteria for landmark and registration clinical trials. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, 17 ‐ 21 June 2025. Wiley. doi: 10.1002/hon.70096_626 |
|
2025 Conference Publication Treatment of newly‐diagnosed follicular lymphoma with Rituximab, golcadomide +/‐ nivolumab‐ interim analysis of the phase II TOP‐FLOR studyMartynchyck, A., Chong, G., Barraclough, A., Ratnasingam, S., Marconi, T., Palmer, J. B., Keane, C., Lee, S. T. B., Scott, A. M., Romano, A., Churilov, L., Lee, D. and Hawkes, E. A. (2025). Treatment of newly‐diagnosed follicular lymphoma with Rituximab, golcadomide +/‐ nivolumab‐ interim analysis of the phase II TOP‐FLOR study. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, 17 ‐ 21 June 2025. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.70094_230 |
|
2025 Journal Article Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRIO’Shaughnessy, Jack, Martynchyk, Arina, Lee, Sze Ting, Chong, Geoff, Agrawal, Shivam, Tatarczuch, Maciej, Azryn, Nariza Alysa, Gregory, Gareth P., Churilov, Leonid, Wang, Michael, Keane, Colm and Hawkes, Eliza A. (2025). Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRI. Neuro-Oncology Advances, 7 (1) vdaf090, vdaf090. doi: 10.1093/noajnl/vdaf090 |
|
2025 Journal Article Nivolumab and rituximab in treatment naive follicular lymphoma: the phase II '1st FLOR' studyBarraclough, Allison, Lee, Sze Ting, Burgess, Melinda, Churilov, Leonid, Chong, Geoffrey, Lee, Denise, Gilbertson, Michael, Fancourt, Tineke, Manos, Kate, Ritchie, David, Koldej, Rachel M, Scott, Andrew, Keane, Colm and Hawkes, Eliza A (2025). Nivolumab and rituximab in treatment naive follicular lymphoma: the phase II '1st FLOR' study. Blood Advances, 9 (6), 1432-1441. doi: 10.1182/bloodadvances.2024015487 |
